Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB/N female mice

Abstract

FVB/N wild type and transgenic HER-2/neu FVB/N female mice breed at N.N. Petrov Research Institute of Oncology were under observation until natural death without any special treatment. Age-related dynamics of body weight, food consumption and parameters of carbohydrate and lipid metabolism, level of nitric oxide, malonic dialdehyde, catalase, Cu, Zn-superoxide dismutase, vascular endothelial growth factor were studied in both mice strains. The parameters of life span and tumor pathology were studied as well. Cancer-prone transgenic HER-2/neu mice developed in 100 % multiple mammary adenocarcinomas and died before the age of 1 year. Forty tree percent of long-lived wild type mice survived the age of 2 years and 19 %-800 days. The total tumor incidence in wild type mice was 34 %. The age-associated changes in the level of serum IGF-1, glucose and insulin started much earlier in transgene HER-2/neu mice as compared with wild type FVB/N mice. It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis.

The effects of different doses of thymulin in vivo and in vitro on some biological properties of bone marrow-derived multipotent mesenchymal stromal cells in mice of different strains

“…It is also possible that differences in MMSCs differentiation potential of the studied control mice can be related to strain-dependent features of the functional state of the neuroendocrine system. For example, in FVB/N mice, the level of thyroxine (T4) in the blood is almost three times higher than that of 129/Sv mice, while in rats deficient in T4, the differentiation of MMSCs in the osteogenic direction is strongly inhibited [32,33,34]. It has been shown that melatonin stimulates differentiation of osteoblast precursors, increases osteoblast activity and expression of collagen type 1, osteopontin and osteocalcin [11,35,36].…”

Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice

“…Petrov National Medical Research Center of Oncology for about 20 years originates from Charles River Laboratories [17]. The female mice, which develop multiple spontaneous mammary adenocarcinomas starting from about 6 months of age, have been extensively used at our laboratory to test the effects of different substances on mammary cancer [18][19][20][21][22][23]. In particular, it has been shown that 1 month of exposure to melatonin alone does not influence tumor growth in 6-month-old mice [17].…”

“…Mice were randomized between the groups with the matching mean tumor node volumes. The number of tumors was not controlled, and it ranged from 3 to 6 as multiple tumor nodes developed in the used mouse strain [21]. Exact number of tumors in each study group is indicated in Table 1.…”

“…Mice treated with AT or CAF at ZT03 were designated as AT 03 or CAF 03 , respectively. The AT 03 animals additionally treated with melatonin provided over a different days of the study were denoted as AT 03 MT (-6, 21) , AT 03 MT (-6, -1) , and AT 03 MT (1,21) , where the subscript numbers in parentheses indicate the number of days before (−) or after the day of commencement of chemotherapy. The same principle was followed to denote the CAF-treated groups, for example, CAF 03 MT (-6, 21) , and to chemotherapy administered at ZT09, for example, CAF 09 MT (-6, 21) .…”

Study of the Effect of Lomustin on Her2-Positive Breast Cancer in FVB/N Her-2 Transgenic Mice

“…Петрова» Минздрава России. Эти мыши отличаются значительной частотой развития спонтанных опухолей молочных желез у самок, иногда они возникают и у самцов [7,8].…”